What are the effects of levetiracetam tablets?

Levetiracetam tablets are a solid drug with certain color differences. It is a drug used to treat epilepsy and is suitable for children. However, this drug has certain usage, dosage, contraindications, and precautions. However, there are still many people who do not understand this drug or do not know about it. So what is the effect of levetiracetam tablets?

Levetiracetam tablets are used as an adjunctive treatment for partial seizures in adults and children over 4 years of age with epilepsy.

Properties: This product is an oval film-coated tablet (250 mg is a blue tablet, 500 mg is a yellow tablet, and 1000 mg is a white tablet). All tablets are white after removing the coating.

Indications: For adjunctive treatment of partial seizures in adults and children over 4 years of age with epilepsy.

Dosage and Administration (1) Route of administration: Oral. It needs to be swallowed with an appropriate amount of water and its use is not affected by food.

(2) Administration method and dosage

The initial treatment dose for adults (>18 years) and adolescents (12-17 years) weighing ≥50 kg is 500 mg twice a day. Based on clinical effect and tolerability, the daily dose can be increased to 1500 mg twice a day. The dose should be increased or decreased by 500 mg/time, twice daily, every 2-4 weeks.

For elderly patients (≥65 years old), adjust the dose according to the renal function status (see the description of patients with impaired renal function below for details).

The initial treatment dose for children aged 4 to 11 years and adolescents (12-17 years) weighing ≤ 50 kg is 10 mg/kg twice a day. Based on clinical effect and tolerability, the dose can be increased to 30 mg/kg twice a day. Dose changes should be increased or decreased by 10 mg/kg twice daily every two weeks. The lowest effective dose should be used whenever possible. For children and adolescents weighing ≥50 kg, the dosage is the same as that for adults.

The safety data summarized from adult clinical studies showed that the incidence of adverse reactions in the drug group and the placebo group were similar, at 46.4% and 42.2%, respectively. Among them, serious adverse reactions were 2.4% and 2.0% respectively. The most common adverse reactions are drowsiness, fatigue, and dizziness, which often occur at the beginning of treatment. The incidence and severity of CNS-related adverse reactions will decrease over time. There is no obvious dose-related adverse reactions of levetiracetam.